Immune checkpoint inhibitors (ICIs), a class of immunotherapeutic agents that blocks immune inhibitory receptors, or immune checkpoints such as CTLA-4, PD-1 and PD-L1, can reactivate anti-cancer immunity, facilitating tumor elimination [26]. This evidence concerns the gene CD274 and cancer.